Benjamin Nemoz1, David Ternant2, Sébastien Bailly3,4, Elodie Gautier-Veyret1,3,5, Jean-François Jourdil1, Bruno Bonaz6, Françoise Stanke-Labesque1,3,5. 1. Laboratory of Pharmacology, Toxicology and Pharmacogenetics, Grenoble-Alpes University Hospital, Grenoble, France. 2. Laboratory of Pharmacology-Toxicology, CHRU de Tours University Hospital, France. 3. INSERM U1042, HP2, Grenoble, France. 4. EFCR Laboratory, Pole Thorax et Vaisseaux, Grenoble Alpes University Hospital, Grenoble, France. 5. Univ. Grenoble Alpes, Grenoble, France. 6. Division of Hepato-Gastroenterology, University Hospital Grenoble-Alpes, France.
Abstract
AIMS: Therapeutic drug monitoring (TDM) of infliximab (IFX) appears to be beneficial for patients with inflammatory bowel disease (IBD). However, the recommended target concentrations depend partly on the method used to quantify IFX. Since we recently developed a liquid chromatography-tandem mass spectrometry method to quantify IFX, we aimed to determine IFX trough concentrations (Cmin) associated with biological remission. METHODS: We retrospectively measured IFX Cmin in sera from 55 patients with IBD, on IFX maintenance therapy, and for whom demographic, biological and clinical data were collected from medical records. A threshold of IFX Cmin associated with biological remission (defined by C-reactive protein < 5 mg l-1 and faecal calprotectin <150 μg g-1 ) was determined using receiver operating characteristics analysis. RESULTS: IFX Cmin ranged from <1 mg l-1 to 57.2 mg l-1 . IFX Cmin were higher (P = 0.038) in patients with biological remission and a cut-off of IFX Cmin set to 6.2 mg l-1 was associated with biological remission (sensitivity = 0.75, 95% confidence interval 0.58-0.75; specificity = 0.61, 95% confidence interval 0.39-0.83). CONCLUSION: Liquid chromatography-tandem mass spectrometry measurement of IFX Cmin and the determination of a new threshold of IFX Cmin associated with biological remission are new steps towards IFX treatment personalization in patients with IBD.
AIMS: Therapeutic drug monitoring (TDM) of infliximab (IFX) appears to be beneficial for patients with inflammatory bowel disease (IBD). However, the recommended target concentrations depend partly on the method used to quantify IFX. Since we recently developed a liquid chromatography-tandem mass spectrometry method to quantify IFX, we aimed to determine IFX trough concentrations (Cmin) associated with biological remission. METHODS: We retrospectively measured IFX Cmin in sera from 55 patients with IBD, on IFX maintenance therapy, and for whom demographic, biological and clinical data were collected from medical records. A threshold of IFX Cmin associated with biological remission (defined by C-reactive protein < 5 mg l-1 and faecal calprotectin <150 μg g-1 ) was determined using receiver operating characteristics analysis. RESULTS:IFX Cmin ranged from <1 mg l-1 to 57.2 mg l-1 . IFX Cmin were higher (P = 0.038) in patients with biological remission and a cut-off of IFX Cmin set to 6.2 mg l-1 was associated with biological remission (sensitivity = 0.75, 95% confidence interval 0.58-0.75; specificity = 0.61, 95% confidence interval 0.39-0.83). CONCLUSION: Liquid chromatography-tandem mass spectrometry measurement of IFX Cmin and the determination of a new threshold of IFX Cmin associated with biological remission are new steps towards IFX treatment personalization in patients with IBD.
Authors: A J Yarur; V Kanagala; D J Stein; F Czul; M A Quintero; D Agrawal; A Patel; K Best; C Fox; K Idstein; M T Abreu Journal: Aliment Pharmacol Ther Date: 2017-02-17 Impact factor: 8.171
Authors: Maria Alice V Willrich; David L Murray; David R Barnidge; Paula M Ladwig; Melissa R Snyder Journal: Int Immunopharmacol Date: 2015-07-25 Impact factor: 4.932
Authors: Ellen M H Schmitz; Daan van de Kerkhof; Dörte Hamann; Joost L J van Dongen; Philip H M Kuijper; Luc Brunsveld; Volkher Scharnhorst; Maarten A C Broeren Journal: Clin Chem Lab Med Date: 2016-07-01 Impact factor: 3.694